[A24-129] Tislelizumab (oesophageal squamous cell carcinoma, first line) – Benefit assessment according to §35a Social Code Book V
Last updated 18.06.2025
Project no.:
A24-129
Commission:
Commission awarded on 20.12.2024 by the Federal Joint Committee (GBA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adults with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma that is not treatable with curative intent, whose tumours express PD-L1 with a Tumour Area Positivity score ≥ 5%
- Patients with tumour cell PD-L1 expression ≥ 1% or a combined positive score (CPS) ≥ 10; first-line treatment: added benefit not proven
- Patients with no tumour cell PD-L1 expression ≥ 1% and no CPS ≥ 10; first-line treatment: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
The current version 1.1 of the Dossier assessment replaces version 1.0 published on 01.04.2025.
https://doi.org/10.60584/A24-129_V1.1_en